Novalar Appoints Steven J. Semmelmayer to its Board of Directors

Wednesday, August 22, 2007 General News J E 4
SAN DIEGO, Aug. 22 Novalar Pharmaceuticals, Inc.,announced today the appointment of Steven J. Semmelmayer to the company'sBoard of Directors. Mr. Semmelmayer brings over 27 years of managementexperience in the medical and dental industries to the board of Novalar.

"Throughout his career Steve has played a central role in the successfulcommercialization of several dental innovations," said Donna Janson, Presidentand CEO of Novalar. "He is an excellent addition to the Board and hissignificant experience in the dental industry will be extremely valuable asthe company moves towards the anticipated 2008 launch of our novel localanesthetic reversal agent, NV-101."

Currently Mr. Semmelmayer serves as President, Chairman and CEO of LEDMedical Diagnostics Inc., and its subsidiary, LED Dental Inc., an innovativecompany dedicated to the early detection of oral cancer. He joined LED inearly 2007.

Mr. Semmelmayer began his career at Ormco Orthodontics, a leader in theorthodontic products market, where he held numerous sales and marketingpositions. In 1993, he became General Manager and then President of KerrCorporation, one of the industry's largest manufacturers of professionaldental consumable products. He presided over Kerr for twelve years, growingthe company from $120 million to almost $400 million in revenue through bothinternal initiatives and acquisitions. In 2005, Mr. Semmelmayer was named thePresident of the Professional Dental Group of Kerr's parent, Sybron DentalSpecialties, a position he maintained until Sybron was sold to DanaherCorporation for $2.2 billion.

"I am delighted to join the Board at such an exciting time," added Mr.Semmelmayer. "I look forward to working with Donna and the management team asthe company prepares for the anticipated launch of NV-101."

About Novalar Pharmaceuticals, Inc.

San Diego-based Novalar Pharmaceuticals, Inc. is a privately-held dentalspecialty pharmaceutical company dedicated to developing and commercializingnovel oral healthcare solutions. The company's initial product offering,NV-101, is being evaluated as a local anesthetic reversal agent and wasdeveloped to rapidly reverse the lingering and debilitating lip and tonguenumbness associated with local dental anesthesia. For more information, visit

SOURCE Novalar Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Despite Flat HMO Market, Blue Cross Blue Shield of...
China Sky One Medical Issues Financial Guidance fo...